KalVista's EKTERLY® Wins First-Line Pediatric HAE Recommendation

Event summary

  • EKTERLY® (sebetralstat) recommended as first-line therapy for adolescents 12+ in new international pediatric HAE guideline.
  • Recommendation based on clinical trial data showing efficacy, rapid symptom relief, and favorable safety profile.
  • Guideline emphasizes early intervention, addressing historical delays in treatment for adolescents.
  • KalVista aims to submit new drug application for sebetralstat in patients aged 2 to 11 in Q3 2026.
  • EKTERLY currently approved in 7 countries, with additional global launches anticipated in 2026.

The big picture

KalVista's inclusion in international guidelines underscores the growing acceptance of oral on-demand therapies in pediatric HAE treatment. The shift from injectable to oral treatments addresses significant unmet needs in adolescent care, potentially expanding market opportunities. The company's strategic focus on pediatric formulations positions it to capture a larger share of the rare disease treatment market.

What we're watching

Regulatory Momentum
Whether KalVista can sustain this regulatory success with approvals for younger age groups.
Market Penetration
The pace at which EKTERLY gains adoption in international markets beyond the US and Germany.
Clinical Trial Outcomes
How data from the KONFIDENT-KID trial will impact future regulatory decisions and market positioning.